Prevalence of FGFR2b Protein Overexpression in Advanced Gastric
Cancers During Prescreening for the Phase III FORTITUDE-101
Trial

J 2025

Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial

RHA, Sun Young; Yanqiao ZHANG; Anneli ELME; Roberto Pazo CID; Ahmet ALACACIOGLU et al.

Základní údaje

Originální název

Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial

Autoři

Vydání

JCO PRECISION ONCOLOGY, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2025, 2473-4284

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.600 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00140755

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Advanced Gastric Cancers; FGFR2b Protein Overexpression

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 3. 2025 14:25, Mgr. Tereza Miškechová

Anotace

V originále

PURPOSEFibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression is an emerging biomarker in gastric cancer and gastroesophageal junction cancer (GC). We assessed FGFR2b protein overexpression prevalence in nearly 3,800 tumor samples as part of the prescreening process for a global phase III study in patients with newly diagnosed advanced or metastatic GC.METHODSAs of June 28, 2024, 3,782 tumor samples from prescreened patients from 37 countries for the phase III FORTITUDE-101 trial (ClinicalTrials.gov identifier: NCT05052801) were centrally tested for FGFR2b protein overexpression by immunohistochemistry (IHC) and had evaluable results. FGFR2b positivity was defined as both any % tumor cells (TC) and >= 10% TC exhibiting moderate-to-strong (2+/3+) membranous FGFR2b staining. Prevalence was analyzed across patient and sample characteristics.RESULTSFGFR2b protein overexpression at any % and >= 10%, 2+/3+ TC positivity was 37.8% (1,428/3,782 [95% CI, 36.2 to 39.3]) and 16.2% (612/3,782 [95% CI, 15 to 17.4]), respectively. Of any %, 2+/3+ TC-positive tumors, 42.9% (612/1,428 [95% CI, 40.3 to 45.4]) were FGFR2b >= 10%, 2+/3+ TC positive. FGFR2b prevalence was not notably different within multiple patient and sample characteristics examined (age, sex, collection method [biopsy v resection], collection site, location of primary tumor, and geographic region).CONCLUSIONAs of the data cutoff date, we report the largest prevalence assessment of FGFR2b protein overexpression in GC with more than one third (37.8%) of patients with GC exhibiting FGFR2b protein overexpression (any % TC, 2+/3+) by a validated IHC assay. Approximately 16% of patients had FGFR2b protein overexpression in >= 10% of TC. FGFR2b prevalence was similar across geographic regions and within defined patient and sample variables regardless of the level of expression.

Citovat

RHA, Sun Young; Yanqiao ZHANG; Anneli ELME; Roberto Pazo CID; Ahmet ALACACIOGLU; Dimitrios C ZIOGAS; Kohei SHITARA; Anastasija RANCEVA; Radim NĚMEČEK; Armando SANTORO; Carlos Alberto CALDERON; Krittiya KORPHAISARN; Tracy DAVIS; Anita ZAHLTEN-KUEMELI; Christopher CONN; Mengyao TAN; Hayden HONEYCUTT a Zev A WAINBERG. Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial. JCO PRECISION ONCOLOGY. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2025, roč. 9, January 2025, s. 1-10. ISSN 2473-4284. Dostupné z: https://doi.org/10.1200/PO-24-00710.

@article{2481379,
   author = {Rha, Sun Young and Zhang, Yanqiao and Elme, Anneli and Cid, Roberto Pazo and Alacacioglu, Ahmet and Ziogas, Dimitrios C and Shitara, Kohei and Ranceva, Anastasija and Němeček, Radim and Santoro, Armando and Calderon, Carlos Alberto and Korphaisarn, Krittiya and Davis, Tracy and ZahltenandKuemeli, Anita and Conn, Christopher and Tan, Mengyao and Honeycutt, Hayden and Wainberg, Zev A},
   article_location = {PHILADELPHIA},
   article_number = {January 2025},
   doi = {https://doi.org/10.1200/PO-24-00710},
   keywords = {Advanced Gastric Cancers; FGFR2b Protein Overexpression},
   language = {eng},
   issn = {2473-4284},
   journal = {JCO PRECISION ONCOLOGY},
   title = {Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial},
   url = {https://ascopubs.org/doi/10.1200/PO-24-00710},
   volume = {9},
   year = {2025}
}

TY  - JOUR
ID  - 2481379
AU  - Rha, Sun Young - Zhang, Yanqiao - Elme, Anneli - Cid, Roberto Pazo - Alacacioglu, Ahmet - Ziogas, Dimitrios C - Shitara, Kohei - Ranceva, Anastasija - Němeček, Radim - Santoro, Armando - Calderon, Carlos Alberto - Korphaisarn, Krittiya - Davis, Tracy - Zahlten-Kuemeli, Anita - Conn, Christopher - Tan, Mengyao - Honeycutt, Hayden - Wainberg, Zev A
PY  - 2025
TI  - Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial
JF  - JCO PRECISION ONCOLOGY
VL  - 9
IS  - January 2025
SP  - 1-10
EP  - 1-10
PB  - LIPPINCOTT WILLIAMS & WILKINS
SN  - 24734284
KW  - Advanced Gastric Cancers
KW  - FGFR2b Protein Overexpression
UR  - https://ascopubs.org/doi/10.1200/PO-24-00710
N2  - PURPOSEFibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression is an emerging biomarker in gastric cancer and gastroesophageal junction cancer (GC). We assessed FGFR2b protein overexpression prevalence in nearly 3,800 tumor samples as part of the prescreening process for a global phase III study in patients with newly diagnosed advanced or metastatic GC.METHODSAs of June 28, 2024, 3,782 tumor samples from prescreened patients from 37 countries for the phase III FORTITUDE-101 trial (ClinicalTrials.gov identifier: NCT05052801) were centrally tested for FGFR2b protein overexpression by immunohistochemistry (IHC) and had evaluable results. FGFR2b positivity was defined as both any % tumor cells (TC) and >= 10% TC exhibiting moderate-to-strong (2+/3+) membranous FGFR2b staining. Prevalence was analyzed across patient and sample characteristics.RESULTSFGFR2b protein overexpression at any % and >= 10%, 2+/3+ TC positivity was 37.8% (1,428/3,782 [95% CI, 36.2 to 39.3]) and 16.2% (612/3,782 [95% CI, 15 to 17.4]), respectively. Of any %, 2+/3+ TC-positive tumors, 42.9% (612/1,428 [95% CI, 40.3 to 45.4]) were FGFR2b >= 10%, 2+/3+ TC positive. FGFR2b prevalence was not notably different within multiple patient and sample characteristics examined (age, sex, collection method [biopsy v resection], collection site, location of primary tumor, and geographic region).CONCLUSIONAs of the data cutoff date, we report the largest prevalence assessment of FGFR2b protein overexpression in GC with more than one third (37.8%) of patients with GC exhibiting FGFR2b protein overexpression (any % TC, 2+/3+) by a validated IHC assay. Approximately 16% of patients had FGFR2b protein overexpression in >= 10% of TC. FGFR2b prevalence was similar across geographic regions and within defined patient and sample variables regardless of the level of expression.
ER  -

RHA, Sun Young; Yanqiao ZHANG; Anneli ELME; Roberto Pazo CID; Ahmet ALACACIOGLU; Dimitrios C ZIOGAS; Kohei SHITARA; Anastasija RANCEVA; Radim NĚMEČEK; Armando SANTORO; Carlos Alberto CALDERON; Krittiya KORPHAISARN; Tracy DAVIS; Anita ZAHLTEN-KUEMELI; Christopher CONN; Mengyao TAN; Hayden HONEYCUTT a Zev A WAINBERG. Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial. \textit{JCO PRECISION ONCOLOGY}. PHILADELPHIA: LIPPINCOTT WILLIAMS \&{} WILKINS, 2025, roč.~9, January 2025, s.~1-10. ISSN~2473-4284. Dostupné z: https://doi.org/10.1200/PO-24-00710.

Přehled o publikaci